Urologic Oncology: Seminars and Original Investigations
Volume 27, Issue 4 , Pages 382-390 , July 2009

XAF1 mRNA expression improves progression-free and overall survival for patients with advanced bladder cancer treated with neoadjuvant chemotherapy

  • Marcos B. Pinho, MSc.

      Affiliations

    • Division of Clinical and Translational Research, Research Coordination (CPQ), Instituto Nacional de Câncer (INCA), Rio de Janeiro, Brazil
    • ,
  • Fernanda Costas, B.S.

      Affiliations

    • Division of Clinical and Translational Research, Research Coordination (CPQ), Instituto Nacional de Câncer (INCA), Rio de Janeiro, Brazil
    • ,
  • João Sellos, B.S.

      Affiliations

    • Division of Clinical and Translational Research, Research Coordination (CPQ), Instituto Nacional de Câncer (INCA), Rio de Janeiro, Brazil
    • ,
  • Rodrigo Dienstmann, M.D.

      Affiliations

    • Division of Clinical and Translational Research, Research Coordination (CPQ), Instituto Nacional de Câncer (INCA), Rio de Janeiro, Brazil
    • ,
  • Patricia B. Andrade, M.D.

      Affiliations

    • Eli Lilly do Brasil Ltda., São Paulo, Brazil
    • ,
  • Daniel Herchenhorn, M.D.

      Affiliations

    • Clinical Oncology Service, Instituto Nacional de Câncer (INCA), Rio de Janeiro, Brazil
    • ,
  • Fábio Afonso Peixoto, M.D.

      Affiliations

    • Clinical Oncology Service, Instituto Nacional de Câncer (INCA), Rio de Janeiro, Brazil
    • ,
  • Valdelice O. Santos, R.N.

      Affiliations

    • Division of Clinical and Translational Research, Research Coordination (CPQ), Instituto Nacional de Câncer (INCA), Rio de Janeiro, Brazil
    • ,
  • Isabele A. Small, MSc.

      Affiliations

    • Division of Clinical and Translational Research, Research Coordination (CPQ), Instituto Nacional de Câncer (INCA), Rio de Janeiro, Brazil
    • ,
  • Denise P. Guimarães, M.D., Ph.D.

      Affiliations

    • Division of Clinical and Translational Research, Research Coordination (CPQ), Instituto Nacional de Câncer (INCA), Rio de Janeiro, Brazil
    • ,
  • Carlos G. Ferreira, M.D., Ph.D.

      Affiliations

    • Division of Clinical and Translational Research, Research Coordination (CPQ), Instituto Nacional de Câncer (INCA), Rio de Janeiro, Brazil
    • Corresponding Author InformationCorresponding author. Tel.: +55-21-32331421; fax: +55-21-32331411

Received 15 January 2008 ,Revised 4 March 2008 ,Accepted 9 March 2008.

References 

  1. Takata R, Katagiri T, Kanehira M, et al. Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res. 2005;11:2625–2636
  2. Instituto Nacional de Câncer and Ministério da Saúde Cancer no Brasil: Dados dos registros de câncer de base populacional. INCA, Rio de Janeiro (2006).
  3. Baffa R, Letko J, McClung C, et al. Molecular genetics of bladder cancer: Targets for diagnosis and therapy. J Exp Clin Cancer Res. 2006;25:145–160
  4. Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guérin immunotherapy for recurrent TA, T1, and carcinoma in situ transitional cell carcinoma of the bladder: A randomized Southwest Oncology Group Study. J Urol. 2000;163:112494;>9.
  5. Gschwend JE, Simon J, Volkmer B, et al. Chemotherapy of bladder cancer (Systemic therapy with reduced toxicity). Urology. 2003;42:1445–1449
  6. von der MH, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin vs. methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, Phase III study J Clin Oncol. 2000;18:3068–3077
  7. de Braud F, Maffezzini M, Vitale V, et al. Bladder cancer. Crit Rev Oncol Hematol. 2002;41:89–106
  8. Robert J, Vekris A, Pourquier P, et al. Predicting drug response based on gene expression. Crit Rev Oncol Hematol. 2004;51:205–227
  9. Makin G, Dive C. Apoptosis and cancer chemotherapy. Trends Cell Biol. 2001;11:S22–S26
  10. Wright CW, Duckett CS. Reawakening the cellular death program in neoplasia through the therapeutic blockade of IAP function. J Clin Invest. 2005;115:2673–2678
  11. Schimmer AD, Dalili S, Batey RA, et al. Targeting XIAP for the treatment of malignancy. Cell Death Differ. 2006;13:179–188
  12. Schimmer AD. Inhibitor of apoptosis proteins: Translating basic knowledge into clinical practice. Cancer Res. 2004;64:7183–7190
  13. Devi GR. XIAP as target for therapeutic apoptosis in prostate cancer. Drug News Perspect. 2004;17:127–134
  14. Emamaullee J, Liston P, Korneluk RG, et al. XIAP overexpression in islet β-cells enhances engraftment and minimizes hypoxia-reperfusion injury. Am J Transplant. 2005;5:1297–1305
  15. Ma TL, Ni PH, Zhong J, et al. Low expression of XIAP-associated factor 1 in human colorectal cancers. Chin J Dig Dis. 2005;6:10–14
  16. Creagh EM, Murphy BM, Duriez PJ, et al. Smac/DIABLO antagonizes ubiquitin ligase activity of inhibitor of apoptosis proteins. J Biol Chem. 2004;279:26906–26914
  17. Shiozaki EN, Shi Y. Caspases, IAPs, and Smac/DIABLO: Mechanisms from structural biology. Trends Biochem Sci. 2004;29:486–494
  18. Althaus J, Siegelin MD, Dehghani F, et al. The serine protease Omi/HtrA2 is involved in XIAP cleavage and in neuronal cell death following focal cerebral ischemia/reperfusion. Neurochem Int. 2007;50:172–180
  19. Trencia A, Fiory F, Maitan MA, et al. Omi/HtrA2 promotes cell death by binding and degrading the anti-apoptotic protein ped/pea-15. J Biol Chem. 2004;279:46566–46572
  20. Hegde R, Srinivasula SM, Datta P, et al. The polypeptide chain-releasing factor GSPT1/eRF3 is proteolytically processed into an IAP-binding protein. J Biol Chem. 2003;278:38699–38706
  21. Deveraux QL, Takahashi R, Salvesen GS, et al. X-linked IAP is a direct inhibitor of cell-death proteases. Nature. 1997;388:300–304
  22. Fong WG, Liston P, Rajcan-Separovic E, et al. Expression and genetic analysis of XIAP-associated factor 1 (XAF1) in cancer cell lines. Genomics. 2000;70:113–122
  23. Liston P, Fong WG, Kelly NL, et al. Identification of XAF1 as an antagonist of XIAP anti-caspase activity. Nat Cell Biol. 2001;3:128–133
  24. Leaman DW, Chawla-Sarkar M, Vyas K, et al. Identification of X-linked inhibitor of apoptosis-associated factor-1 as an interferon-stimulated gene that augments TRAIL Apo2L-induced apoptosis. J Biol Chem. 2002;277:28504–28511
  25. Leaman DW, Chawla-Sarkar M, Jacobs B, et al. Novel growth and death related interferon-stimulated genes (ISGs) in melanoma: Greater potency of IFN-β compared with IFN-α2. J Interferon Cytokine Res. 2003;23:745–756
  26. Wang J, Peng Y, Sun YW, et al. All-trans retinoic acid induces XAF1 expression through an interferon regulatory factor-1 element in colon cancer. Gastroenterology. 2006;130:747–758
  27. Byun DS, Cho K, Ryu BK, et al. Hypermethylation of XIAP-associated factor 1, a putative tumor suppressor gene from the 17p13.2 locus, in human gastric adenocarcinomas. Cancer Res. 2003;63:7068–7075
  28. Fang X, Liu Z, Fan Y, et al. Switch to full-length of XAF1 mRNA expression in prostate cancer cells by the DNA methylation inhibitor. Int J Cancer. 2006;118:2485–2489
  29. Ng KC, Campos EI, Martinka M, et al. XAF1 expression is significantly reduced in human melanoma. J Invest Dermatol. 2004;123:1127–1134
  30. Perrelet D, Perrin FE, Liston P, et al. Motoneuron resistance to apoptotic cell death in vivo correlates with the ratio between X-linked inhibitor of apoptosis proteins (XIAPs) and its inhibitor, XIAP-associated factor 1. J Neurosci. 2004;24:3777–3785
  31. Herchenhorn D, Dienstmann R, Peixoto FA, et al. Phase II trial of neoadjuvant gemcitabine and cisplatin in patients with resectable bladder carcinoma. Int Braz J Urol. 2007;5:630–638
  32. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors (European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada). J Natl Cancer Inst. 2000;92:205–216
  33. Kempkensteffen C, Hinz S, Schrader M, et al. Gene expression and promoter methylation of the XIAP-associated Factor 1 in renal cell carcinomas: Correlations with pathology and outcome. Cancer Lett. 2007;254:227–235
  34. Lee MG, Huh JS, Chung SK, et al. Promoter CpG hypermethylation and down-regulation of XAF1 expression in human urogenital malignancies: Implication for attenuated p53 response to apoptotic stresses. Oncogene. 2006;25:5807–5822
  35. Qi R, Gu J, Zhang Z, et al. Potent antitumor efficacy of XAF1 delivered by conditionally replicative adenovirus vector via caspase-independent apoptosis. Cancer Gene Ther. 2007;14:82–90
  36. Chen GH, Lin FR, Ren JH, et al. Expression and significance of X-linked inhibitor of apoptosis protein and its antagonized proteins in acute leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2006;14:639–643
  37. Ng KC, Campos EI, Martinka M, et al. XAF1 expression is significantly reduced in human melanoma. J Invest Dermatol. 2004;123:1127–1134
  38. Byun DS, Cho K, Ryu BK, et al. Hypermethylation of XIAP-associated factor 1, a putative tumor suppressor gene from the 17p13.2 locus, in human gastric adenocarcinomas. Cancer Res. 2003;63:7068–7075
  39. Byun DS, Cho K, Ryu BK, et al. Hypermethylation of XIAP-associated factor 1, a putative tumor suppressor gene from the 17p13.2 locus, in human gastric adenocarcinomas. Cancer Res. 2003;63:7068–7075
  40. Ishiguro M, Iida S, Uetake H, et al. Effect of combined therapy with low-dose 5-Aza-2′-deoxycytidine and irinotecan on colon cancer cell line HCT-15. Ann Surg Oncol. 2006;14:1752–1762
  41. Jang JY, Kim HJ, Chi SG, et al. Frequent epigenetic inactivation of XAF1 by promoter hypermethylation in human colon cancers. Korean J Gastroenterol. 2005;45:285–293
  42. Zou B, Chim CS, Zeng H, et al. Correlation between the single-site CpG methylation and expression silencing of the XAF1 gene in human gastric and colon cancers. Gastroenterology. 2006;131:1835–1843
  43. Straszewski-Chavez SL, Visintin IP, Karassina N, et al. XAF1 mediates TNF-α-induced apoptosis and XIAP cleavage by acting through the mitochondrial pathway. J Biol Chem. 2007;282:13059–13072
  44. Cullen KJ, Yang Z, Schumaker L, et al. Mitochondria as a critical target of the chemotherapeutic agent cisplatin in head and neck cancer. J Bioenerg Biomembr. 2007;39:43–50
  45. Yang Z, Schumaker LM, Egorin MJ, et al. Cisplatin preferentially binds mitochondrial DNA and voltage-dependent anion channel protein in the mitochondrial membrane of head and neck squamous cell carcinoma: Possible role in apoptosis. Clin Cancer Res. 2006;12:5817–5825
  46. Christgen M, Schniewind B, Jueschke A, et al. Gemcitabine-mediated apoptosis is associated with increased CD95 surface expression but is not inhibited by DN-FADD in Colo357 pancreatic cancer cells. Cancer Lett. 2005;227:193–200
  47. Ferreira CG, van der Valk P, Span SW, et al. Expression of X-linked inhibitor of apoptosis as a novel prognostic marker in radically resected non-small cell lung cancer patients. Clin Cancer Res. 2001;7:2468–2474
  48. Liu SS, Tsang BK, Cheung AN, et al. Antiapoptotic proteins, apoptotic and proliferative parameters, and their prognostic significance in cervical carcinoma. Eur J Cancer. 2001;37:1104–1110

PII: S1078-1439(08)00065-3

doi: 10.1016/j.urolonc.2008.03.016

Urologic Oncology: Seminars and Original Investigations
Volume 27, Issue 4 , Pages 382-390 , July 2009

Article Tools

* Image Usage & Resolution